The North America newborn screening market is witnessing robust growth, with revenue increasing from 980 Million USD in 2020 to 1,370 Million USD in 2025, ultimately projected to reach 2,230 Million USD by 2035. This growth trajectory is attributed to increased test volumes, expanding screening panels, and greater public health investments. The upward trend underscores the region's commitment to improving neonatal health outcomes through early and comprehensive diagnostic programs, further supported by rapid technological innovation.
Read More - https://bussinessinsights.com/research-report/north-america-newborn-screening-market
Dry blood spot screening maintains the highest market share by application in 2025, underpinned by its widespread use in the detection of multiple metabolic and genetic conditions from a single sample. Hearing screening secures the second-largest share due to expanded government mandates and hospital protocols, while diagnosis of cystic fibrosis and sickle cell disease continues to be prioritized. Critical congenital heart disease screening is also gaining momentum, supported by advancements in pulse oximetry and related technologies.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-newborn-screening-market
Who are the key players in North America Newborn Screening Market industry?
The top five players in the North America Newborn Screening Market include PerkinElmer Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Natus Medical Incorporated, and Agilent Technologies, Inc. These companies offer leading technologies, diagnostic assays, and instruments, driving innovation and expanding screening capabilities across the market.
What is the North America Newborn Screening Market growth?
The North America Newborn Screening Market is experiencing significant growth, with a CAGR above 7% in recent years. Growth is fueled by product launches from companies like PerkinElmer, such as advanced tandem mass spectrometry platforms, and government initiatives expanding newborn screening panel requirements.
Which segment accounted for the largest North America Newborn Screening Market share?
The largest market share is held by the dried blood spot (DBS) test segment in applications, owing to its accuracy, ease of sample collection, and cost-effectiveness. DBS is widely used for screening genetic, metabolic, and endocrine disorders in newborns, making it the preferred choice across North American healthcare facilities.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com